Multiple Dose Study of MK-2828 in Participants With Type 2 Diabetes (MK-2828-003)

This study tests a new investigational drug called MK-2828 — given in multiple doses — in people with Type 2 diabetes to see if it is safe and effective at improving blood sugar control. The drug works by reducing inflammation through blocking a specific pathway in the immune system (NLRP3). **You may be eligible if...** - You have had Type 2 diabetes for at least 1 year - Your HbA1c (a measure of long-term blood sugar control) is 10% or below - Your weight has been stable for at least 3 months - Your BMI is between 25 and 40 - You manage your diabetes with lifestyle changes or up to 3 oral medications **You may NOT be eligible if...** - You have Type 1 diabetes or other types of diabetes - You have significant heart disease, heart failure, or have had a stroke or heart attack within 6 months - You have had weight-loss surgery or use weight-loss devices - You have serious allergies to related drugs Talk to your doctor to see if this trial is right for you.